Tevogen Bio (NASDAQ:TVGNW – Get Free Report) is anticipated to post its results before the market opens on Wednesday, February 25th. Analysts expect Tevogen Bio to post earnings of ($0.03) per share for the quarter.
Tevogen Bio Trading Up 6.3%
TVGNW stock opened at $0.05 on Monday. Tevogen Bio has a 52 week low of $0.03 and a 52 week high of $0.09. The firm has a 50 day moving average of $0.04 and a 200 day moving average of $0.05.
Tevogen Bio Company Profile
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Further Reading
- Five stocks we like better than Tevogen Bio
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
